1271810-25-3

Basic information

• Product Name: Trans-1-(Tert-Butoxycarbonyl)-4-Methylpiperidine-3-Carboxylic Acid
• Synonyms: Trans-1-(Tert-Butoxycarbonyl)-4-Methylpiperidine-3-Carboxylic Acid;Trans-1-(Tert-Butoxycarbonyl)-4-Methylpiperidine-3-Carboxylic Acid(WX611433)
• CAS NO: 1271810-25-3
• Molecular Formula: C12H21NO4
• Molecular Weight: 243.29944
• Mol File: 1271810-25-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Trans-1-(Tert-Butoxycarbonyl)-4-Methylpiperidine-3-Carboxylic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: Trans-1-(Tert-Butoxycarbonyl)-4-Methylpiperidine-3-Carboxylic Acid(1271810-25-3)
• EPA Substance Registry System: Trans-1-(Tert-Butoxycarbonyl)-4-Methylpiperidine-3-Carboxylic Acid(1271810-25-3)

Safety Data

• Hazardous Substances Data: 1271810-25-3(Hazardous Substances Data)

Upstream product

• 1201192-62-2 1-(tert-butyl) 3-methyl 4-methylpiperidine-1,3-dicarboxylate 
• 908244-98-4 methyl 4-methylpiperidine-3-carboxylate 
• 33402-75-4 4-methylnicotinic acid methyl ester 
• 3222-50-2 4-methylnicotinic acid 
• 1262523-08-9 (+/-)-4-methyl-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 94015-05-1 4-methylpyridine-3-carboxylic acid hydrochloride 
• 67-56-1 methanol 
• 3430-22-6 3-Bromo-4-methylpyridin 
• 116140-15-9 4-methylpiperidine-3-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1207853-61-9 trans-racemic tert-butyl 3-amino-4-methylpiperidine-1-carboxylate 

Relevant articles and documents

[1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS

The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.

[1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND

The present invention relates to a novel [l,2,4]triazolo[l,5-a]pyrimidin-yl derivative of formula (1) as inhibitor of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compound, to processes for preparing such compound and compositions, and to the use of such compound and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.